Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

Unlike other breast cancer subtypes, patients with triple negative breast cancer (TNBC) have poor outcomes and no effective targeted therapies, leaving an unmet need for therapeutic targets. Efforts to profile these tumors have revealed the PI3K/AKT/mTOR pathway as a potential target. Activation of...

Full description

Bibliographic Details
Main Authors: Wei Wen, Emily Marcinkowski, David Luyimbazi, Thehang Luu, Quanhua Xing, Jin Yan, Yujun Wang, Jun Wu, Yuming Guo, Dylan Tully, Ernest S. Han, Susan E. Yost, Yuan Yuan, John H. Yim
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cells
Subjects:
TNBC
eribulin
PI3K/AKT/mTOR
everolimus
combination
synergy
Online Access:https://www.mdpi.com/2073-4409/8/9/1010

Similar Items

Similar Items